摘要
目的:研究晚期肺癌患者化疗5个周期T淋巴细胞表面抑制性分子(TIM3、PD-1、CTLA-4)的变化。方法:应用流式细胞仪技术检测33例初治晚期肺癌患者化疗5个周期T淋巴细胞表面抑制性分子的表达变化。并与23例健康志愿者作对比。结果:化疗前晚期肺癌患者外周血T淋巴细胞表面抑制性分子的表达明显高于健康对照组,差异具有统计学意义(P<0.05)。化疗后19例临床疗效评价为PR或SD的患者,其外周血CD4+TIM3+T淋巴细胞、CD8+TIM3+T淋巴细胞、CD4+PD-1+T淋巴细胞、CD8+PD-1+T淋巴细胞比例在化疗5个周期中降低,差异有统计学意义(P<0.05);而CD4+CTLA-4+T淋巴细胞、CD8+CTLA-4+T淋巴细胞比例呈现下降趋势,与化疗前相比无显著性差异(P>0.05)。结论:晚期肺癌患者的免疫功能处于抑制状态。有效的化疗可降低T淋巴细胞表面抑制性分子表达,改善肿瘤对免疫功能的抑制。
Objective: The tumorigenesis, progression, and metastasis of lung cancer are mostly governed by the immunosuppres- sive profile. This study aimed to explore the levels of various immunosuppressive inhibitory molecules in lung-cancer patients subject- ed to different chemotherapy cycles. Methods: Thirty-three patients with advanced lung cancer (ALC; stages III-IV) without receiving prior chemotherapy and 23 healthy subjects were enrolled in our study. Peripheral blood samples were collected from the patients be- fore each chemotherapy cycle. The inhibitory markers expressed in T cells such as TIM3, PD-1, and CTLA4 were analyzed by flow cy- tometry. Results: The percentages ofCD4+ TIM3+, CD8+ TIM3+, CD4+ PD-1+, CD8+ PD-1+, CD4+ CTLA-4+, and CD8+ CTLA-4+ T cells in the peripheral blood of the ALC patients were significantly higher compared to the controls. The percentage of CD4t TIM3 +, CD8+ TIM3+, CD4+ PD-1+, and CD8+ PD-1+ T lymphocytes in the peripheral blood of patients (n=19) who achieved PR or SD significantly de- creased after five cycles of chemotherapy (P〈0.05). Similarly, the percentages of CD4+ CTLA-4+ and CD8+CTLA-4+ T cells in the pa- tients also decreased after five cycles of treatment. Conclusion: The immune status of ALC patients was evidently suppressed. Effec- tive chemotherapy successfully potentiated effective immune responses by downregulating inhibitory molecules in T cells.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2013年第16期960-964,共5页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金(编号:81171986)
NFSC-NIH生物医学合作项目(编号:812111102)
卫生部科学研究基金(编号:20110110001)
河南省科技厅基础与前沿技术研究基金(编号:112300410153,122300410155)资助~~
关键词
晚期肺癌
化疗
流式细胞术
T淋巴细胞
表面抑制分子
advanced lung cancer, chemotherapy, flow cytometry, T cell, inhibitory molecule